INTRODUCTION
In the previous paper the technical aspects of the mucin-clot prevention test which was standardized by McClean (1) have been described. Friou and Wenner (2) using the mucin-clot prevention test have demonstrated the clinical significance of an inhibitory substance in human serum capable of neutralizing an enzyme elaborated by a strain of hemolytic streptococcus. The amount of inhibitory substance was shown by them to be greater in the sera of patients with rheumatic fever than in patients early in the course of uncomplicated hemolytic streptococcal infections or normal individuals. A brief historical background of the work preceding that of Friou and Wenner has been presented in the previous paper.
The purpose of this paper is to report the clinical application of the muein-clot prevention test in the determination of the antihyaluronidase titre of sera of patients with rheumatic fever, hemolytic streptococcal infections, miscellaneous other diseases, and normal individuals.
MATERIALS AND METHODS
The materials and methods used in these studies were exactly as described in the previous paper. Figure 1 . Subsequently the mean of 40 sera from patients convalescent from scarlet fever and other acute beta hemolytic streptococcal infections was determined to be slightly less than 1: 2048. That of ten patients with active rheumatoid arthritis was 1:1024. Forty-one sera from patients with nonstreptococcal infectious diseases including tuberculosis, syphilis, bacterial and "virus" pneumonia, leprosy, Vincent's angina, gonococcus urethritis, etc. had a mean titre slightly less than 1: 2048. The mean antihyaluronidase titre for 41 sera from the patients with non-streptococcal infectious diseases combined with the ten sera from patients with rheumatoid arthritis was slightly less than 1:2048. Sera from all the 258 patients with rheumatic fever had a mean antihyaluronidase titre of 1: 4096. The sera from patients with rheumatic fever were analyzed further according to the state of activity of the rheumatic process at the time the blood was collected. The mean-antihyaluronidase titres for these different groups of sera were as follows: For rheumatic fever, active, acute, it was higher than 1: 16, 384 being slightly nearer to 1:16,384 than the next highest dilution which would be 1:32,768. In this group of patients 4'72 were those whose illness had begun within three weeks of the time the serum was collected and who still had high fever, acute arthritis, tachycardia, carditis, and other clinical and laboratory evidence of acute rheumatic fever. These patients were all receiving salicylates by mouth in therapeutic doses. The highest individual antihyaluronidase titres were observed in this group of patients. The titre of some sera in this group was as high as 1: 262,-144 and furthermore this high titre was not observed in sera from any individuals other than those with rheumatic fever, active, acute. The mean titre for the group with rheumatic fever, active, i.e., those whose illness was more than three weeks old but who still had evidence of ac- Figure 1 . This figure shows graphically the wider range of titres and higher mean titre of the rheumatic fever sera compared with sera from patients with hemolytic streptococcal infections, non-streptococcal infectious diseases, and normal individuals.
One of the important results of these studies was the finding that the mean antihyaluronidase titre of the sera from patients with rheumatic fever, active, acute, was significantly higher than the mean titre of sera from normal individuals or from any other group of patients except those with rheumatic fever, active, subsiding. tients with rheumatic fever, active, acute, and the gradual decrease in mean antihyaluronidase titre from the group, with rheumatic fever, active, acute, to the group with rheumatic fever, inactive.
DISCUSSION
In these studies the contention of Friou and Wenner (2) that the amount of inhibitory substance against streptococcal hyaluronidase in sera from patients with rheumatic fever was greater than in sera from patients early in the course of uncomplicated hemolytic streptococcal infections or from normal individuals has been confirmed. It also has been demonstrated that the serum antihyaluronidase titre in patients early in the course of active rheumatic fever is significantly higher than the antihyaluronidase titres of sera from any other group of patients studied including patients with active, subsiding, or inactive rheumatic fever, hemolytic streptococcal disease, and non-streptococcal infectious diseases. The results do not yield information which indicates that patients with streptococcal disease have a higher mean antihyaluronidase titre than patients with other infectious diseases. However, further studies of the antihyaluronidase titre in patients during the course of streptococcal infection and rheumatic fever along with the antifibrinolysin and antistreptolysin "O" titres are being done and will be reported later.
No attempt has been made to study the effect of salicylates on the antihyaluronidase titre of patients or the effect of salicylates on hyaluronidase in vivo and in vitro, but from the recent reports by Guerra (5), Pike (6), Dorfman et al. (7), and Meyer (8) , it would appear that salicylates do inhibit the spreading effect of hyaluronidase in skin but have no inhibitory effect on testicular or bacterial hyaluronidase in vivo in concentrations obtained therapeutically.
Obviously much more investigation is necessary before the meaning of these results will be fully understood or before this test can be proposed as a diagnostic measure.
SUMMARY AND CONCLUSIONS 1. Studies of the determination of antihyaluronidase titres of sera from patients with rheumatic fever, hemolytic streptococcal infections, miscellaneous non-streptococcal infectious diseases, and normal individuals have been presented.
2. The mean antihyaluronidase titre of sera from patients with rheumatic fever was significantly higher than the mean titre of sera from the other groups of patients studied.
